Bufrolin

Bufrolin is a Cromoglycate (histamine release inhibitor) analog and a high potency agonist of GPR35. Bufrolin promotes interactions between β-arrestin-2 and either human GPR35a or rat GPR35. Bufrolin also serves as antiallergic mast cell stabilizer and inhibit an anti-inflammatory response inducible by the internalization peptide. Bufrolin acts as an anti-inflammatory agent to be used in research of delivering pharmacol linked with internalization peptide[1][2][3].

Product Specifications

CAS Number

[54867-56-0]

UNSPSC

12352005

Target

GPR35 ; Histamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bufrolin.html

Purity

95.16

Solubility

10 mM in DMSO

Smiles

O=C1C2=C3C(C(C=C(C(O)=O)N3)=O)=CC(CCCC)=C2NC(C(O)=O)=C1

Molecular Formula

C18H16N2O6

Molecular Weight

356.33

References & Citations

[1]MacKenzie AE, et al. The antiallergic mast cell stabilizers lodoxamide and bufrolin as the first high and equipotent agonists of human and rat GPR35. Mol Pharmacol. 2014 Jan;85 (1) :91-104. |[2]Tymianski M, et al. Co-administration of an agent linked to an internalization peptide with an anti-inflammatory: United States, US8933013 B2. 2015-01-13. |[3]Church M K, et al. Comparison of sodium cromoglycate derivatives, anti-histamines and β-stimulants on histamine release from human lung in vitro[J]. International Archives of Allergy and Immunology, 1981, 66 (Suppl. 1) : 281-282.